Oncology
3 drugs are in development for Clear Cell Renal Cell Carcinoma.
- Companies
- 3
- Clinical trials
- 24
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Clear Cell Renal Cell Carcinoma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Casdatifan | Arcus Biosciences, Inc. (RCUS) |
Phase 1(1)
| Drug | Company |
|---|---|
| CTX131 | CRISPR Therapeutics AG (CRSP) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| XmAb819 | Xencor Inc (XNCR) |
About this indication
Clear Cell Renal Cell Carcinoma context
Oncology·MeSH: Carcinoma, Renal Cell (D002292)
Narrower concept of MeSH descriptor Renal Cell Carcinoma
Prevalence
48.0 / 100K
Incidence
15.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Clear Cell Renal Cell Carcinoma?
BioSniper tracks 3 drugs in development for Clear Cell Renal Cell Carcinoma across 3 companies.
How many clinical trials target Clear Cell Renal Cell Carcinoma?
There are 24 clinical trials targeting Clear Cell Renal Cell Carcinoma tracked by BioSniper.
What is the prevalence of Clear Cell Renal Cell Carcinoma?
The estimated prevalence of Clear Cell Renal Cell Carcinoma is approximately 48.0 per 100,000 population.